Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma
Nuri Lee, Jae‐Lyun Lee, Ju‐Yeun Lee
Topics & Concepts
MedicinePazopanibSorafenibAxitinibSunitinibInternal medicineRenal cell carcinomaAdverse effectAngiogenesisOncologyVascular endothelial growth factorTyrosine-kinase inhibitorCancerHepatocellular carcinomaVEGF receptorsRenal cell carcinoma treatmentAngiogenesis and VEGF in CancerChemotherapy-induced organ toxicity mitigation